A phase II trial of girentuximab in combination with low-dose interferon alpha-2a in patients with metastatic clear cell renal cell cancer.

Trial Profile

A phase II trial of girentuximab in combination with low-dose interferon alpha-2a in patients with metastatic clear cell renal cell cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2006

At a glance

  • Drugs Girentuximab; Interferon alpha-2a
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors WILEX AG
  • Most Recent Events

    • 19 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top